Chief Executive Officer and Executive Chairman
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors. Prior to OncoSec, he served as Vice President of Finance and Operations at Inovio Pharmaceuticals, where he raised over $160 million through multiple financings and several licensing transactions. His management experience spans corporate finance, M&A integration, in-licensing of key intellectual property, strategy implementation, corporate transactions and collaborations with leading universities and key global opinion leaders. Mr. Dhillon also the co-founded BeCancerPositive.org, an online community for cancer patients. In 2014, he was a finalist in Ernst & Young’s “Entrepreneur of the Year” competition. Mr. Dhillon holds a BA (Honors) in political science and a minor in business administration from Simon Fraser University.
Dennis Kim, MD, MBA
Chief Medical Officer
Dr. Kim is a physician and biotechnology executive with over 20 years of experience in drug and product development as well as corporate strategy in biotech and medical technology. Prior to joining Emerald, Dr. Kim was Chief Medical Officer at Zafgen, Senior Vice President of Medical and Clinical Affairs at Orexigen Therapeutics, Chief Medical Officer at EnteroMedics, and Executive Director of Corporate Strategy at Amylin Pharmaceuticals. He holds an MD from the University of Health Sciences, The Chicago Medical School, an MBA from UCSD Rady School of Management, and a BS in Biology from the University of California. In addition to being board-certified in internal medicine, Dr. Kim completed the Endocrinology and Metabolism Specialty Fellowship Training Program at the UCSD School of Medicine.
Executive Director, Clinical Operations
Ms. Chen has 20 years of global clinical research experience working with early and late-stage biotech companies, particularly in the planning and execution of clinical trials for a variety of indications, including oncology, hepatology, autoimmune, and orphan diseases. Prior to joining Emerald, Ms. Chen served as the Head of Clinical Operations at Zafgen, Inc., where she was involved in study design, managing study conduct, and overseeing clinical trial budgets and timelines across multiple clinical programs. Additionally, Ms. Chen held various positions in clinical operations at Salmedix and Ionis, and consulting positions at Cephalon, Altair Therapeutics, Auspex Pharmaceuticals, MedGene, Inc., Cabrellis Pharmaceuticals, and Santaris Pharma.Ms. Chen is a graduate of the University of California, San Diego.